Work

The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials

Year: 2017

Type: article

Abstract: The alpha-7 nicotinic acetylcholine receptor (α7 nAChR), consisting of homomeric α7 subunits, is a ligand-gated Ca2+-permeable ion channel implicated in cognition and neuropsychiatric disorders. Enhancement of α7 nAChR function is considered to be a potential therapeutic strategy aiming at ameliorating cognitive deficits of neuropsychiatric disorders such as Alzheimer's disease (AD) and schizophrenia. Currently, a number of α7 nAChR modulators have been reported and several of them have advanced into clinical trials. In this brief review, we outline recent progress made in understanding the role of the α7 nAChR in multiple neuropsychiatric disorders and the pharmacological effects of α7 nAChR modulators used in clinical trials.

Source: Acta Pharmaceutica Sinica B

DOI: 10.1016/j.apsb.2017.09.001

Authors: Taoyi Yang, Ting Xiao, Qi Sun, Kewei Wang

Institutions: Peking University, State Key Laboratory of Natural and Biomimetic Drugs, Qingdao University

Language: English

Topic: Nicotinic Acetylcholine Receptors Study

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,600